重组人血小板生成素治疗免疫性血小板减少症的效果分析及对炎症因子的调控作用研究

摘要

目的 分析重组人血小板生成素治疗免疫性血小板减少症的效果及对炎症因子的调控作用.方法 对2011年4月至2015年12月期间诊治的免疫性血小板减少症患者120例进行研究,以同期健康体检者100例为对照组.分析重组人血小板生成素的治疗效果及治疗前后患者血清中炎症因子水平的变化.结果 与对照组相比,治疗前免疫性血小板减少症患者血小板、白细胞计数、血清白细胞介素1、白细胞介素2、白细胞介素6、白细胞介素10、肿瘤坏死因子α(TNF-α)、干扰素(IFN-γ)、内皮素及其受体、瘦素及其受体、基质金属蛋白酶(MMP)2和MMP9水平明显升高(P＜0.05);经重组人血小板生成素治疗后免疫性血小板减少症后患者血小板数明显升高(P＜0.05),而血红蛋白、白细胞计数和丙氨酸氨基转移酶(ALT)及总胆红素(TBil)水平无显著差异(P＞0.05);且治疗后血清白细胞介素1、白细胞介素2、白细胞介素6、白细胞介素10、 TNF-α、IFN-γ、内皮素及其受体、瘦素及其受体、MMP2和MMP9水平明显降低(P＜0.05).结论 重组人血小板生成素治疗患者免疫性血小板减少症的效果显著,可能与其调控血清炎症反应蛋白有关.%Objective The present research aimed to explore the effect of recombinant human thrombopoietin on immune thrombocytopenia and its effects on serum inflammatory factors.Methods 120 cases of immune thrombocytopenia patients in our department from Apr 2011 to Dec 2015 were enrolled in this research.The effects of the treatment and serum inflammatory factors were analyzed.100 healthy subjects were taken as control group.Results The results showed that the serum IL-1,IL-2,IL-6,IL-10,TNF-α,IFN-γ,endothelin and leptin and their receptors,MMP2/9 were increased greatly in immune thrombocytopenia patients when compared with those of control group (P＜0.05).The results showed that the immune thrombocytopenia was alleviated greatly while the RBC,WBC,ALT and TBil were at the same level when compared with pre-treatment.The results also revealed that the serum IL-1,IL-2,IL-6,IL-10,TNF-α,IFN-γ,endothelin and leptin and their receptors,MMP2/9 were decreased significantly,with significant differences when compared with control group (P＜0.05).Conclusion Recombinant human thrombopoietin is effective on immune thrombocytopenia therapy which maybe related with the regulation of serum inflammatory factors.